Swiss pharmaceutical company Novartis Pharma AG (SIX:NOVN) (NYSE:NVS) reported on Wednesday that twice-yearly Leqvio (inclisiran) has shown significant LDL-C reduction in a Phase III study involving patients who were at low or moderate risk of developing atherosclerotic cardiovascular disease (ASCVD) and not receiving lipid-lowering therapy.

The positive topline results of the V-MONO study add to the growing evidence supporting Leqvio's effectiveness in various ASCVD prevention settings. Novartis plans to present results from this trial at an upcoming medical meeting and share the data with regulatory agencies including the US Food and Drug Administration (FDA).

Novartis is also conducting other studies evaluating Leqvio's potential for primary and secondary ASCVD prevention.